RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/28/2026

1. ON
2. SYNA
3. SPY
4. MU
5. AAPL
6. VEON
7. SPCX
8. DRI
9. NVDA
10. FDXF

Go back to RedHill Biopharma (RDHL) Study Shows opaganib's Strong Inhibition of COVID-19 Delta Variant

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

August 26, 2021 6:00 AM EDT

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant... More